Short answer
Surgery Partners, Inc. (SGRY) filed an 8-K current report with the SEC on September 17, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.01 (Completion of Acquisition or Disposition of Assets). Completed sale of Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health on September 14, 2026.
Surgery Partners, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Completed sale of Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health on September 14, 2026
- Approximately $796.6 million aggregate consideration, subject to closing cash, indebtedness, expenses and post-closing adjustments
- Proceeds primarily earmarked for debt repayment, supporting balance-sheet deleveraging
- Disposition included hospital operations, substantially all related assets and certain liabilities
- Financial statements and pro forma effects to follow under Item 9.01, important for assessing ongoing revenue and earnings changes
Item EX-99.1 · Exhibit EX-99.1
- Proposed sale of Mountain View and Idaho Falls hospitals to Intermountain Health for approximately $796.6M
- Estimated net cash proceeds of $586.5M after $219.7M closing cash and indebtedness and $9.6M working-capital adjustments
- Pro forma cash rises to $708.8M from $216.7M, while long-term debt declines to $3,331.1M from $3,648.3M
- Revenue decreases to $1,287.8M for six months ended June 30, 2026 and $2,586.1M for 2025
- Pro forma net loss attributable to Surgery Partners widens to $69.2M and $108.2M, respectively, versus historical losses of $50.9M and $77.9M
Item EX-99.2 · Exhibit EX-99.2
- Completed Idaho Falls sale to Intermountain Health for $797M gross and $587M net cash proceeds
- $1.15B transaction value, implying approximately 7x LTM adjusted EBITDA and 17x average distributions
- Debt reduction primary proceeds use, with leverage expected to improve 30bps from 4.4x at Q2 2026
- Portfolio becomes pure-play short-stay surgical, eliminating inpatient pediatrics, obstetrics, neonatology and pharmacy services
- Updated 2026 guidance: revenue $3.08B-$3.18B and adjusted EBITDA at least $489M; pro forma revenue $2.60B-$2.67B and EBITDA at least $414M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Surgery Partners, Inc. 8-K filings
Get the next SGRY 8-K as it lands
Follow SGRY for push alerts, or ask the research agent what this filing means.